$TNGX

Tango Therapeutics, Inc.

Tango Therapeutics is a biotechnology company developing targeted cancer therapies for patients selected by molecular biomarkers. Its small-molecule drug candidates are designed to act on cancer cells with specific genetic alterations. The company’s clinical programs include vopimetostat, an MTAP-deleted selective PRMT5 inhibitor being studied alone and with RAS inhibitors for non-CNS cancers; TNG456, a brain-penetrant PRMT5 inhibitor for MTAP-deleted solid tumors, with a focus on glioblastoma; and TNG260, a CoREST inhibitor studied with pembrolizumab in patients with checkpoint inhibitor resistant STK11-mutant, KRAS wild-type lung cancer. TNG961, an HBS1L-targeting molecular glue, is in IND-enabling development. Tango also uses its discovery platforms to identify and validate oncology targets and advance additional cancer drug candidates. It relies on third-party manufacturers for investigational products and collaborates with other companies on clinical trials and drug combinations. Tango Therapeutics is headquartered in Boston, Massachusetts.

No enriched coverage for $TNGX in the last 7 days.

—
$475K
Crystal Adam
100%
See all $TNGX insider activity →
Med

JPMorgan highlights stock on Analyst Focus List after 3Q results

JPMorgan analyst Brian Cheng maintained Tango Therapeutics (TNGX) on its Analyst Focus List with an Overweight rating after 3Q results met expectations. Key catalysts include January updates on '456 and vopi therapies. The price target was raised to $47 from $46. The company is progressing studies in pancreatic and other cancers.

Jefferies raises Tango Therapeutics stock price target on trial data

Jefferies raised its price target for Tango Therapeutics (TNGX) to $65 from $60, citing positive trial data for pancreatic cancer treatments. The stock has surged 187% over the past year. Other analysts also raised price targets, with a consensus Strong Buy rating. The company expects regulatory updates and more data in 2027.

TNGX sentiment & insider activity

Recent TNGX coverage spans financial news, earnings and regulation.

In the last 30 days, TNGX insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($475K). The most active reporter was Crystal Adam, President, R&D, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving TNGX

AlphAI scores every news story that mentions TNGX with an AI model for sentiment and relevance, and aggregates insider trades from Tango Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TNGX

Score

JPMorgan raises Tango Therapeutics price target to $47 on pipeline

JPMorgan raised its price target for Tango Therapeutics (TNGX) to $47, citing pipeline updates and strong analyst sentiment. The stock is up 157% YTD, with consensus price targets ranging from $24 to $69. JPMorgan expects key data updates in January. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55. Tango reported a Q2 2026 loss of $0.37 per share, wider than estimates.

Tango Therapeutics Reports Q3 2026 Net Loss of $68.4 Million

Tango Therapeutics reported a Q3 2026 net loss of $68.4M, up from a $15.9M profit a year earlier, due to higher expenses and zero collaboration revenue. Cash reserves totaled $977.5M. The company shared promising Phase 1/2 results for vopimetostat combined with daraxonrasib in pancreatic cancer, with an 82% response rate and 88% nine-month survival rate. Tango plans to initiate a Phase 3 trial in 2027 and focus on PRMT5-targeted therapies.

$TNGXHighAI 9/10Earnings

Tango Therapeutics Reports Third Quarter 2026 Financial Results

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progre

Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals

AstraZeneca (AZN) and Daiichi Sankyo (4568.T) won EU approval for Enhertu in breast cancer. Pfizer (PFE) expanded Talzenna-Xtandi use in prostate cancer. AbbVie (ABBV) got FDA approval for subcutaneous SKYRIZI in Crohn's disease. Artiva (ARTV) to cut 94% of workforce after halting AlloNK development. Tango (TNGX) plans 14% layoffs. Rakovina (RKV.V) and Celvion used AI to prioritize cancer types for ATR inhibitor. 60 Degrees (SXTP) partners for alpha-gal syndrome research.

$TNGXMedAI 8/10

Wedbush raises Tango Therapeutics stock price target on trial data

Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.

$TNGXMedAI 8/10

Stifel raises Tango Therapeutics stock price target on trial data

Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.

$TNGXHighAI 8/10

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) fell 6.8% in pre-market trading after releasing Phase 1/2 trial results showing 82% response rate and 88% progression-free survival in pancreatic cancer patients. The decline follows a 28% stock surge ahead of the data release and coincides with broader market sell-offs. An affiliate officer's planned share sale also contributed to pressure.

Related tickers